Objective To observe the efficacy of rosiglitazone in the treatment of obesetype 2 diabetics.
目的观察罗格列酮治疗肥胖型2型糖尿病的疗效。
2
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obesetype 2 diabetic mellitus(T2DM).
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
3
Through the TCM researches about obesetype 2 DM, we presume that the pathogenesis of IR in type 2 DM is Qi deficiency of spleen and kidney, blockage of phlegm and blood stasis.